News

Pfizer, Gilead, GSK to lead $150 bn infectious diseases mkt by 2029: Report Pharma giants Pfizer, Gilead Sciences, and GSK are expected to collectively generate 62 per cent of total infectious disease drug sales between 2023 and 2029, according to a report on Wednesday. The report by GlobalData, a leading data and analytics company, showed that the infectious diseases market is forecast to grow at a compound annual growth rate (CAGR) of 5.7 per cent between 2023 and 2029 to reach an impressive $150 billion in annual sales in 2029. Despite a 63.8 per cent declin...
Pfizer, Gilead, GSK to lead $150 bn infectious diseases mkt by 2029: Report
Pfizer, Gilead, GSK to lead $150 bn infectious diseases mkt by 2029: Report
Source: IANS
20/07/2023 10:10:33 AM
Hold Pfizer Ltd For Target Rs . 3830 - ICICI Direct Slowdown in key power brands impacts sales…   About the stock: Pfizer collectively addresses 15 therapy areas in domestic formulations with a portfolio of over 150 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio in the last few years to improve the productivity of its core brands. * Fourth largest multinational pharma company in India * Manufacturing facility in Goa with run rate of 1 billion tablets per ...
Hold Pfizer Ltd For Target Rs . 3830 - ICICI Direct
Hold Pfizer Ltd For Target Rs . 3830 - ICICI Direct
Source: ICICI Direct
31/05/2023 3:10:08 PM
Pfizer`s India unit posts 3% rise in Q4 profit Pfizer Ltd, the Indian unit of U.S. pharmaceutical group Pfizer Inc, on Monday reported a 3.1% rise in fourth-quarter profit, helped by lower raw material expenses. Net profit for the quarter ended March 31 rose to 1.30 billion rupees ($15.90 million) from 1.26 billion rupees a year ago, while revenue rose 4.2%. Pfizer also declared a final dividend of 35 rupees per share and a special dividend of 5 rupees per share. For further earnings highlights, click: WHY IT MATTERS Pfizer...
Pfizer`s India unit posts 3% rise in Q4 profit
Pfizer`s India unit posts 3% rise in Q4 profit
Source: Reuters
16/05/2023 9:04:29 AM
Samsung chief visits chip parts manufacturing unit in China Samsung Electronics' Executive Chairman Lee Jae-yong has visited a semiconductor components manufacturing site in China run by a Samsung affiliate, the company said on Sunday, in the first such trip to the neighbouring country in three years. Lee visited the manufacturing facility in Tianjin, operated by Samsung Electro-Mechanics Co and checked the multilayer ceramic capacitors (MLCC) production line, Samsung Electronics said. It marked Lee's first visit to a Samsung plant in Ch...
Samsung chief visits chip parts manufacturing unit in China
Samsung chief visits chip parts manufacturing unit in China
Source: IANS
26/03/2023 3:24:03 PM
Key Stock Ideas: Blackstone, GAIL, Pfizer, SVB - ARETE Securities Blackstone sells 20.50% stake in Sona BLW Precision for Rs 4,917 crore: Private equity firm Blackstone on Monday sold its 20.50 per cent stake in auto component maker Sona BLW Precision Forgings for Rs 4,917 crore through an open market transaction. Blackstone, through its affiliate Singapore VII Topco III Pte Ltd offloaded the shares in Sona BLW. Singapore VII Topco III Pte is a promoter entity in Sona BLW.Monetary Authority of Singapore, Government of Singapore, BNP Paribas Arbitrage,...
Key Stock Ideas: Blackstone, GAIL, Pfizer, SVB - ARETE Securities
Key Stock Ideas: Blackstone, GAIL, Pfizer, SVB - ARETE Securities
Source: ARETE Securities Ltd
14/03/2023 9:30:06 AM
Pfizer inches up after transferring Thane business undertaking to Vidhi Research and Development Pfizer is currently trading at Rs. 3810.40, up by 2.50 points or 0.07% from its previous closing of Rs. 3807.90 on the BSE. The scrip opened at Rs. 3781.10 and has touched a high and low of Rs. 3824.90 and Rs. 3781.10 respectively. So far 350 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4662.35 on 02-Dec-2022 and a 52 week low of Rs. 3761.15 on 14-Feb-2023. Last one week high and low of the scrip stood at Rs...
Pfizer inches up after transferring Thane business undertaking to Vidhi Research and Development
Pfizer inches up after transferring Thane business undertaking to Vidhi Research and Development
Source: Accord Fintech
27/02/2023 3:55:15 PM
Buy Pfizer India Ltd For Target Rs.4,800 - Anand Rathi Shares and Stock Brokers Soft FY23 on a high base; valuations attractive; maintaining a Buy Pfizer’s Q3 revenue slid 8% y/y, 3% q/q, to Rs6.2bn. Even as MinipressXL growth was good, Becosules was flat, while Mucaine, Gelusil and Wysolone declined. The gross margins was steady q/q at 65%. Sequentially, staff costs and other expenses were up 11% each, which led to a 360bp contraction in the EBITDA margin to 32.7%. PAT was Rs1.5bn (up 5% y/y). Management had earlier said in the AGM, that FY23 is expected to be ...
Buy Pfizer India Ltd For Target Rs.4,800 - Anand Rathi Shares and Stock Brokers
Buy Pfizer India Ltd For Target Rs.4,800 - Anand Rathi Shares and Stock Brokers
Source: Anand Rathi Shares and Stock Brokers Ltd
13/02/2023 5:09:11 PM
Buy Pfizer Ltd For Target Rs .5,790 - Centrum Broking Low cost drives earnings  Pfizer reported Q2FY23 result, with overall revenue came flat on YoY and grew 8% QoQ to Rs6.4bn. Despite lower sales, its better cost mix resulted EBITDA growth of 22% YoY and 21% QoQ  to Rs2.3bn with margin expansion of 658bps YoY and 400bps ...
Buy Pfizer Ltd For Target Rs .5,790 - Centrum Broking
Buy Pfizer Ltd For Target Rs .5,790 - Centrum Broking
Source: Centrum Broking Ltd
9/12/2022 11:34:30 AM
Power Pick : Buy Pfizer Ltd For Target Rs.5250 - Anand Rathi Shares and Stock Brokers PFIZER * PFIZER has been under pressure since quiet some time but at this juncture its trading near its crucial WEEKLY support. * Previously the stock turned from this level and we saw a rally towards 6100. * Thus we advise traders to go long in the stock with a stop loss of 4250  BUY TATAMOTORS  CMP : 4586 Target: 5250 Up side : 15% Timeframe : 1 Month     To Read Complete Report & Disclaimer Click Here   Please ...
Power Pick : Buy Pfizer Ltd For Target Rs.5250 - Anand Rathi Shares and Stock Brokers
Power Pick : Buy Pfizer Ltd For Target Rs.5250 - Anand Rathi Shares and Stock Brokers
Source: Anand Rathi Shares and Stock Brokers Ltd
6/12/2022 12:46:06 PM
Hold Pfizer Ltd For Target Rs . 4505 - ICICI Direct Margins upbeat but power brands yet to see uptick… About the stock: Pfizer collectively addresses 15 therapy areas in domestic formulations with a portfolio of over 150 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio in the last few years to improve the productivity of its core brands. * Fourth largest multinational pharma company in India * Manufacturing facility in Goa with run rate of 1 billion tablets per ann...
Hold Pfizer Ltd For Target Rs . 4505 - ICICI Direct
Hold Pfizer Ltd For Target Rs . 4505 - ICICI Direct
Source: ICICI Direct
18/11/2022 2:47:18 PM
Pfizer`s India arm posts profit jump on lower costs, price hikes Pfizer Ltd, the Indian arm of U.S. pharma giant Pfizer Inc, reported a rise in second-quarter profit on Friday, boosted by price hikes and lower input costs. Profit before tax and exceptional item rose to 2.26 billion Indian rupees ($27.97 million) in the three months ended Sept. 30, from 1.75 billion rupees in the year-ago period. The company booked a one-time gain of 1.89 billion rupees on the sale its off-patent and generic medicines business, Upjohn. Pfizer's revenue from ope...
Pfizer`s India arm posts profit jump on lower costs, price hikes
Pfizer`s India arm posts profit jump on lower costs, price hikes
Source: Reuters
11/11/2022 5:44:05 PM
Buy Pfizer Ltd For Target Rs.5,372 - ICICI Securities Cost-control supports margins Pfizer’s Q1FY23 performance beat our estimates on the profitability front driven by strong control over costs. Revenues declined 20.9% YoY (+7.9% QoQ) to Rs5.9bn (I-Sec: Rs.5.9bn) on a high covid-led base. EBITDA margin expanded 230bps QoQ to 32.4% (I-Sec: 30.5%) on account of operating leverage. AdjustedPAT fell 32.6% YoY (on a high base) to Rs1.3bn (I-Sec: Rs1.2bn). We remain positive on the company’s growth visibility with exposure only in domes...
Buy Pfizer Ltd For Target Rs.5,372 - ICICI Securities
Buy Pfizer Ltd For Target Rs.5,372 - ICICI Securities
Source: ICICI Securities Ltd
19/09/2022 12:39:11 PM
Pfizer gains on transferring Upjohn business to Mylan Pharmaceuticals for Rs 180.48 crore Pfizer is currently trading at Rs. 4250.00, up by 30.20 points or 0.72% from its previous closing of Rs. 4219.80 on the BSE. The scrip opened at Rs. 4240.00 and has touched a high and low of Rs. 4250.00 and Rs. 4220.10 respectively. So far 300 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6164.80 on 08-Sep-2021 and a 52 week low of Rs. 4056.00 on 29-Jun-2022. Last one week high and low of the scrip stood at R...
Pfizer gains on transferring Upjohn business to Mylan Pharmaceuticals for Rs 180.48 crore
Pfizer gains on transferring Upjohn business to Mylan Pharmaceuticals for Rs 180.48 crore
Source: Accord Fintech
2/08/2022 12:32:37 PM
Omicron-targeting Covid vax shows high immune response: Pfizer & BioNTech The new Covid shot that specifically targets Omicron variant elicits a strong immune response against the strain, widely known to evade vaccines, Pfizer and BioNTech have said. According to the companies, just a month after administration, a booster dose of the Omicron-adapted monovalent candidates (at 30 and 60 microgram doses) increased neutralising antibodies against Omicron BA.1 to 13.5 and 19.6-fold above pre-booster dose levels. A booster dose of the Omicron-adapted bivalent candi...
Omicron-targeting Covid vax shows high immune response: Pfizer & BioNTech
Omicron-targeting Covid vax shows high immune response: Pfizer & BioNTech
Source: IANS
26/06/2022 3:32:29 PM
Pfizer to offer all its drugs not-for-profit to 45 lower-income countries Pfizer has announced it is to supply all its current and future patent-protected medicines and vaccines on a not-for-profit basis to 45 lower-income countries and is talking to other big drugmakers about similar steps, The Guardian reported. Announcing an "accord for a healthier world" at the World Economic Forum (WEF) annual meeting in Davos, the New York-based pharma firm pledged to provide all its products that are available in the US and Europe on a cost basis to 1.2 billion ...
Pfizer to offer all its drugs not-for-profit to 45 lower-income countries
Pfizer to offer all its drugs not-for-profit to 45 lower-income countries
Source: IANS
26/05/2022 8:31:49 AM
Buy Pfizer Limited Target Rs. 5,314 - ICICI Securities Robust performance; all-round beat Pfizer Limited’s (PFL) Q3FY22 result was above our estimates across parameters. Revenue grew 13.9% YoY to Rs6.8bn (I-Sec est : Rs.6.4bn) led by strong growth in the anti-infectives, gastro and respiratory portfolio. EBITDA margin contracted 430bps YoY (-90bps QoQ) to 28.9% (I-Sec est : 28.5%) led by normalization of ground-level expenses and cost inflation. Adjusted PAT grew 1.9% YoY to Rs1.4bn (I-Sec est.: Rs1.2bn). We remain positive on the compan...
Buy Pfizer Limited Target Rs. 5,314 - ICICI Securities
Buy Pfizer Limited Target Rs. 5,314 - ICICI Securities
Source: ICICI Securities Ltd
16/03/2022 12:36:58 PM
Pfizer rises on entering into business transfer agreement with Mylan Pharmaceuticals Pfizer is currently trading at Rs. 5608.75, up by 36.55 points or 0.66% from its previous closing of Rs. 5572.20 on the BSE. The scrip opened at Rs. 5600.00 and has touched a high and low of Rs. 5650.00 and Rs. 5573.20 respectively. So far 865 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6164.80 on 08-Sep-2021 and a 52 week low of Rs. 4200.00 on 24-Feb-2021. Last one week high and low of the scrip stood at R...
Pfizer rises on entering into business transfer agreement with Mylan Pharmaceuticals
Pfizer rises on entering into business transfer agreement with Mylan Pharmaceuticals
Source: Accord Fintech
4/10/2021 12:37:47 PM
Hold Pfizer Ltd For Target Rs.5,752 - ICICI Securities Exceptional performance Pfizer Limited’s (PFL) reported strong performance beating our estimates across parameters during the quarter. Revenue grew 45.5% YoY to Rs7.5bn (I-Sec: Rs7.2bn) benefiting from strong growth in its top brands. EBITDA margin improved 1460bps QoQ (+190bps YoY) to 38.1% (I-Sec: 27.0%) with sharp decline in S,G&A costs (-20.2% QoQ). Adjusted PAT grew 60.6% YoY to Rs2.0bn (I-Sec: Rs1.8bn). While we remain positive on the company’s growth visibility wi...
Hold Pfizer Ltd For Target Rs.5,752 - ICICI Securities
Hold Pfizer Ltd For Target Rs.5,752 - ICICI Securities
Source: ICICI Securities
2/09/2021 11:16:24 AM
Hold Pfizer Ltd For Target Rs. 5,035 - ICICI Securities Margins impacted by high expenses Pfizer Limited’s (PFL) reported performance was weak during the quarter with it missing the estimates on all fronts. Revenue grew 6.5% YoY to Rs5.3bn (I-Sec: Rs5.7bn) despite company benefiting from its vitamins/minerals/nutrients (VMN) and gastro-intestinal portfolio. EBITDA margin declined 970bps QoQ to 23.5% (ISec: 30.2%) due to higher S,G&A costs (+32% QoQ). Adjusted PAT declined 18.8% YoY to Rs796mn (I-Sec: Rs1.4bn). While we remain posit...
Hold Pfizer Ltd For Target Rs. 5,035 - ICICI Securities
Hold Pfizer Ltd For Target Rs. 5,035 - ICICI Securities
Source: ICICI Securities Ltd
24/06/2021 10:16:14 AM
Buy Pfizer Ltd For Target Rs. 6060 - ICICI Direct Steady annual performance despite disturbances… FY21 revenues grew 4.0% YoY to | 2239 crore with hospital and vaccines business impacted amid the pandemic. EBITDA margins expanded 520 bps to 31.8% YoY due to a better overall operational performance. Decline in other expenses is likely on account of lower promotional and marketing activities related expenses. EBITDA grew 24.4% YoY to | 712 crore. However, PAT de-grew 2.3% YoY to | 498 crore. Delta vis-à-vis EBITDA was due to l...
Buy Pfizer Ltd For Target Rs. 6060 - ICICI Direct
Buy Pfizer Ltd For Target Rs. 6060 - ICICI Direct
Source: ICICI Direct
14/06/2021 9:31:35 AM
Pfizer Q4 net profit down 2.39% at Rs 100.55 cr The company reported standalone net profit of Rs 100.55 crore for the quarter ended March 31, 2021 as compared to Rs 103.01 crore in the same period last year, registering a year-on-year decline of 2.39 per cent. Net revenue of the company rose moderately by 6.52 per cent at Rs 534.76 crore in January-March quarter of this fiscal as against Rs 502.01 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 4.00 per cent to Rs 409.02 crore f...
Pfizer Q4 net profit down 2.39% at Rs 100.55 cr
Pfizer Q4 net profit down 2.39% at Rs 100.55 cr
Source: Dion Global Solutions Ltd
27/05/2021 10:43:36 AM
Pfizer in talks with India for COVID-19 vaccine supplies NEW DELHI  - Pfizer is in talks with the Indian government over supplies of its COVID-19 vaccine, the U.S. drugmaker said on Tuesday, as New Delhi scrambles to bridge shortfalls, having pledged to fast-track approvals for overseas vaccines. "Pfizer remains committed to continuing our engagement with the government of India towards making the Pfizer BioNTech Covid-19 vaccine available for use in the country," a spokeswoman told Reuters in an e-mailed statement. Last week, ...
Pfizer in talks with India for COVID-19 vaccine supplies
Pfizer in talks with India for COVID-19 vaccine supplies
Source: Reuters
25/05/2021 2:38:05 PM
Pfizer in talks with India over expedited approval for COVID-19 vaccine NEW DELHI  - Pfizer is in discussions with the Indian government seeking an "expedited approval pathway" for its COVID-19 vaccine, its CEO Albert Bourla said on LinkedIn on Monday, announcing a donation of medicines worth more than $70 million. "Unfortunately, our vaccine is not registered in India although our application was submitted months ago," he said. "We are currently discussing with the Indian government an expedited approval pathway to make our Pf...
Pfizer in talks with India over expedited approval for COVID-19 vaccine
Pfizer in talks with India over expedited approval for COVID-19 vaccine
Source: Reuters
3/05/2021 12:37:11 PM
Buy Pfizer Limited Target Rs. 180 - Religare Broking Derivative Ideas PFIZER FUTS added around 16% in open interest as LONG buildup was seen in it till closing time. Current chart pattern also indicates further up move in its price. We suggest buying PFIZER 5600 CE as per below levels. Strategy:- BUY PFIZER 5600 CE BETWEEN 120-125 STOP LOSS 95 TARGET 180.   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer http://ex.religareonline.com/disclaimer SEBI Registration number is INZ000174330 ...
Buy Pfizer Limited Target Rs. 180 - Religare Broking
Buy Pfizer Limited Target Rs. 180 - Religare Broking
Source: Religare Broking Ltd
22/04/2021 9:55:14 AM
South African variant may evade protection from Pfizer vaccine, Israeli study says JERUSALEM- The coronavirus variant discovered in South Africa may evade the protection provided by Pfizer/BioNTech's COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is very low and the research has not been peer reviewed. The study, released on Saturday, compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinate...
South African variant may evade protection from Pfizer vaccine, Israeli study says
South African variant may evade protection from Pfizer vaccine, Israeli study says
Source: Reuters
12/04/2021 9:55:21 AM
GlobalSpace Technologies shines on entering into strategic partnership with Pfizer Globalspace Technologies is currently trading at Rs. 61.00, up by 1.55 points or 2.61% from its previous closing of Rs. 59.45 on the BSE. The scrip opened at Rs. 65.35 and has touched a high and low of Rs. 65.35 and Rs. 61.00 respectively. So far 2750 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 135.85 on 25-Aug-2020 and a 52 week low of Rs. 44.00 on 16-Apr-2020. Last one week high and low of the scrip stood...
GlobalSpace Technologies shines on entering into strategic partnership with Pfizer
GlobalSpace Technologies shines on entering into strategic partnership with Pfizer
Source: Accord Fintech
18/02/2021 10:07:45 AM
Singapore expecting shipment delays of Pfizer-BioNTech vaccines SINGAPORE  - Singapore is expecting shipment delays of Pfizer-BioNTech vaccines due to upgrades in Pfizer's manufacturing plant, its health ministry said on Friday. The ministry said the city-state had so far administered first doses of the vaccine to more than 60,000 people and would monitor supplies closely to ensure all Singaporeans and long-term residents are inoculated by the third quarter of 2021.
Singapore expecting shipment delays of Pfizer-BioNTech vaccines
Singapore expecting shipment delays of Pfizer-BioNTech vaccines
Source: Reuters
22/01/2021 4:37:38 PM